New treatment strategies for patients with triple-negative breast cancer

Medicine and Dentistry

• Triple Negative Breast Cancer 100%
• Biological Marker 66%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 33%
• Polyadenylic Acid 33%
• Angiogenesis Inhibitor 33%
• Anthracycline 33%
• Polymerase 33%
• Chemotherapy Agent 33%
• Ribose 33%
• Platinum Derivative 33%
• Hormone Receptor 33%
• Dose Densification 33%
• Tumor Infiltrating Lymphocyte 33%
• Combination Chemotherapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Triple Negative Breast Cancer 100%
• Biological Marker 66%
• Taxane 33%
• Chemotherapy Agent 33%
• Neoplasm 33%
• Hormone Receptor 33%
• Anthracycline 33%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 33%